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Children and adults are different physio-
logically and behaviorally. Children eat and
drink more (based on size), play and act dif-
ferently (e.g., very young children engage in
more hand-to-mouth activity), are still under-
going development, and may be less or more
able to metabolize and excrete certain sub-
stances [reviewed by U.S. EPA (U.S.
Environmental Protection Agency) (2001)].
Because of these differences, children and
adults may differ qualitatively and/or quanti-
tatively in how they are affected by xenobiotic
exposure. Effects of xenobiotics in children
may be completely different from effects from
the same exposure in adults (qualitative differ-
ence). On the other hand, the effect of xeno-
biotic exposure may be similar between
children and adults but may occur to a greater
or lesser extent in the child (quantitative
difference).
Because of the potential differences in
response to xenobiotic exposures, recent con-
cerns have arisen in the scientific and regu-
latory arenas and call for improved safety
assessments pertaining to children’s health.
Children’s health risk assessment is the evalu-
ation of the potential for xenobiotic exposures
to cause any adverse developmental effect,
including growth retardation, malformations,
functional deﬁcits, and lethality. Risk assess-
ment includes evaluating available toxicity
data (hazard identification) and exposure
information (e.g., dose, route, duration,
developmental stage of exposure) to deter-
mine if a xenobiotic causes potential adverse
health effects in humans.
Various initiatives have been undertaken
to address the many challenges in conducting
children’s health risk assessment, including a
number of International Life Sciences
Institute (ILSI)-sponsored projects. This arti-
cle was developed to provide a high-level
overview of the status of hazard identiﬁcation
as it pertains to children’s health. The infor-
mation was used as background material for
an ILSI-sponsored workshop on developing a
framework for assessing risks to children from
exposure to environmental agents (Daston
2004). Therefore, this article is not intended
to be comprehensive but merely provides an
initial overview of hazard identification,
particularly the use of animal models, as an
attempt to identify data gaps in children’s
health risk assessment.
Critical Periods and Important
Milestones in Development
For purposes of risk assessment, the human
life span can be divided into a number of
exposure periods: preconceptional (maternal
and paternal), preimplantation, postimplanta-
tion (organogenesis; ﬁrst trimester), early and
late fetal, premature infant, perinatal, neona-
tal (term), infant, toddler, preteen (prepuber-
tal), adolescent, and adult. Comparable
periods for animal species are not as easily
defined and are dependent on individual
organs or systems. Furthermore, it is apparent
from the work of Hoar and Monie (1981)
and DeSesso (1997) that developmental
events do not occur at the same chronological
age across species. The literature on develop-
mental toxicology (Wilson 1977) and devel-
opmental neurotoxicology (Rodier 1980;
Vorhees 1986) contains many examples of
the stage-specificity of structural and func-
tional damage in laboratory animal species
that depends on developmental age. Thus,
developmental age of maturation is most
relevant for interspecies comparison.
Adverse developmental effects can occur
during any period of the life span. Although it
can be argued that the lifetime of an individ-
ual comprises the period of development, the
most dramatic manifestations of development
occur during the period of maturation to
adult status in both humans and animals. This
period of life includes both prenatal (preim-
plantation, embryonic, fetal periods) and post-
natal (infancy, childhood, adolescence)
development. For purposes of the current
effort, the period of pre- and postnatal
development is considered childhood and is
arbitrarily deﬁned as the period of life encom-
passing conception to 18 years of age in
humans and from conception to sexual matu-
rity in experimental animals. Only recently
have scientific and regulatory concerns
focused on postnatal development and hazard
identification from exposures after birth.
Therefore, more information is currently
known about the details of prenatal
development than those of the postnatal
period.
Organ system development, chronology,
and physical scaling across species. During
development, cells within an organism
change from a state of pluripotency (i.e., abil-
ity to develop into a great number of different
tissue types) to a state of differentiation (i.e.,
commitment to a particular structural and/or
functional role within the body). This
concept of increasing cellular/organ differen-
tiation, or specialization, throughout develop-
ment is depicted in Figure 1 (modiﬁed from
DeSesso 1997). The trend of increasing dif-
ferentiation with maturation occurs in all
species, but the chronological timetables can
be very different from species to species. That
is, the developmental time course for species
with prolonged gestation periods (e.g.,
humans) occurs over a greater period of time
than that of species with shorter gestation
periods (e.g., rats), as illustrated in Figure 2.
Humans reach adulthood in 18–25 years
(depending on the criteria used to measure
adult status), with bursts of developmental
activity during both early childhood and
puberty. In contrast, rats attain adult status
very quickly. The life span of the two species
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development are congruent, regardless of
chronological age (Figure 3)—this is scaling
to physiological time. By doing so, it can be
noted that, based on developmental stages,
birth occurs much earlier in the rat than in
the human. Birth is not a maturational land-
mark; it does not occur at the same develop-
mental stage for each species. Rather, birth is
a physiological event that occurs at different
developmental stages, depending on the
species.
In the 1820s Karl van Baer (1828) made
some observations about differentiation
among species. Looking at prenatal develop-
ment, he noted that the more general features
of an embryo appeared earlier than the more
specialized features, and that as development
progressed, different species diverged mor-
phologically. For example, forelimb buds
appeared early in development and looked
similar across species. Later in development,
the forelimb buds of a fish became fins and
those of a bird became wings, whereas those
of a human became arms.
It is partly because of the morphological
and presumed physiological similarities
among species during the early stages of
development that prenatal toxicity-testing
paradigms have been used so successfully. To
date, researchers have focused generally on
effects mediated during the period of organo-
genesis, when cells and organs are undergoing
early differentiation but species are still rela-
tively similar to one another. Early in devel-
opment, cells and embryos of different species
react similarly to a challenge (e.g., exposure to
a xenobiotic) because at those developmental
stages their cells have not differentiated
greatly. Later in development, the cells of one
organ may react differently to a challenge
than the cells of another organ, and one
species may react differently than another
because of developmental divergence and spe-
cialization. This concept was captured in one
of Wilson’s general principles of teratology:
the response of a developing organism to a
challenge depends on its stage of development
(Wilson 1959, 1973). This principle applies
to postnatal development as well. 
Postnatal development and critical
windows. Prenatal developmental milestones
have historically been morphological and well
deﬁned (reviewed by DeSesso 1997). For the
most part, especially during the embryonic
and early fetal periods, milestones have been
identiﬁed by the emergence/disappearance or
change in form of particular structures. As
development proceeds, the nascent organism
takes on a progressively more mature form.
Thus, the ability to discern milestones
becomes more difficult and tends toward
histological or physiologically based markers
of development such as attainment of blood
pressure, thermal homeostasis (resistance to
cooling), closure of sutures/epiphyses, onset
of glandular secretion, or appearance of
cellular receptors.
In postnatal life some milestones in animal
species are denoted by the appearance of par-
ticular behaviors or neurological activities (e.g.,
acoustic startle response, exploratory behavior,
rearing, mounting). Unlike with prenatal
development, there are few reliable, compara-
tive postnatal milestones in typically used
experimental animals and humans. Without a
database of normal milestone appearance,
derived from many control animals, little
information is available about the normal vari-
ation in these data. This, in turn, leads to obvi-
ous difﬁculties in interpreting such ﬁndings as
a delay in the appearance of a particular mile-
stone. Furthermore, interpretation of some
behaviors is confounded because they are
related to olfaction in macrosmatic species such
as rodents and carnivores, and it is not clear
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Figure 1. Differentiation increases with age of developing organisms. Modiﬁed from DeSesso (1997).
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Figure 2. Time to develop adult characteristics.
Figure 3. Relationship between extent of matura-
tion and birth in rats and humans.that these behaviors have counterparts in
microsmatic species like man. Thus, the rele-
vance of some of these findings will be
problematic for use in risk assessment.
Because a generally accepted suite of
postnatal developmental milestones in animal
species is not yet available, the critical periods
for the developmental processes associated
with those milestones have generally not yet
been defined. Additionally, there may be
more than one critical period of vulnerability
and end point affected. For example, brain
structures have different peak periods of
growth. Therefore, depending on the particu-
lar time of exposure, compounds could differ-
entially affect the structures undergoing peak
development. In a review of animal studies
and their clinical implications, Rodier (1980)
found that exposures occurring at different
stages of brain development had different
effects on brain and behavioral functions. For
example, based on data from azacytidine-
treated mice, hyperactivity seemed to result
from insults that occurred during the middle
part of neuron production (midprenatal
insult), whereas hypoactivity seemed to result
from insults that coincided with cerebellum
proliferation (early prenatal and early postna-
tal insults). Additionally, the developmental
outcome of methamphetamine exposure in
rats depends on the developmental stage at
the time of exposure, both prenatal and post-
natal. Early prenatal exposure results in
anophthalmia, whereas late prenatal exposure
results in folded retina (Acuff-Smith et al.
1996). Early postnatal exposure results in per-
sistent decreases in body weights, whereas late
postnatal exposure results in impaired spatial
learning (Vorhees et al. 1994). Both early and
late postnatal exposures result in impaired
complex learning, demonstrating that there
may be overlap in periods of vulnerability or
that some periods of vulnerability may be
extended in relation to similar functional
development. 
Understanding both the fundamental
biology and the temporal schedule that
underlie the development of whatever mile-
stones are eventually selected is paramount for
performing well-grounded, scientiﬁcally based
risk assessments. Therefore, it is important to
begin by defining important pediatric mile-
stones for growth and development, both
global and organ system speciﬁc. These mile-
stones should be readily assessed by clinicians,
reflect normal maturational processes, be
liable to disruption when normal maturation
is perturbed, and demonstrate susceptibility
to pharmacologic perturbation (i.e., display
properties of dose response and time action).
Subsequently, end points in animal species
analogous to these pediatric milestones should
be identified accordingly. The first step in
identifying such milestones could be to con-
sult pediatricians to determine the key end
points monitored in the clinic and then evalu-
ate their relationships to end points used in
animal models.
Relevance/Predictability of
Extrapolation of Animal Data
to Children’s Risk Assessment
Animal/human concordance has been
reasonably well characterized in two primary
areas pertaining to children’s health: develop-
mental toxicology and developmental neuro-
toxicology. Species comparisons of the
development of physical structures and organ
systems have been made by Otis and Brent
(1954), Hoar and Monie (1981), and
DeSesso (1997). These comparisons enhance
the predictability of the type of damage that
may occur in humans after insult at various
stages of development. Several studies have
assessed the ability of animal models to pre-
dict human risk for developmental toxicity
(Frankos 1985; Hemminki and Vineis 1985;
Holson et al. 1981; Jelovsek et al. 1989;
Kimmel et al. 1984; Newman et al. 1993;
Nisbet and Karch 1983; Schardein 1995;
Schardein and Keller 1989; Schardein et al.
1985). Holson et al. (1981) and Kimmel
et al. (1984), in the most thorough analyses,
evaluated data only from experimental animal
studies and epidemiology studies that met
stringent design criteria [see discussion by
Holson et al. (2000)]. These investigators
concluded that concordance of developmen-
tally adverse effects exists when one considers
all of the measures of developmental toxicity
(death, malformation, growth effects, func-
tional deﬁcit). Strict anatomical concordance
is not always present but is not necessary
when one only needs a signal that develop-
ment may be perturbed. Testing for concor-
dance of identical anatomical aberrations
requires detailed knowledge of comparative
stages of organ system development and toxi-
cokinetic information so that one can com-
pare similar target organ doses at equivalent
stages of development. If such detailed knowl-
edge were available, it would be possible to
test for the ability of an agent to elicit speciﬁc
malformations. 
Table 1 indicates potential developmental
landmarks that have been measured in humans
and/or laboratory animals. This list is not all-
inclusive and requires input from individuals
with pediatric expertise. Tests for acquisition of
these landmarks may differ in humans and lab-
oratory species, but the same basic end point is
being measured. Representation on this list
does not necessarily indicate that these tests are
being conducted routinely or that they are vali-
dated. Several areas such as hormone measure-
ments, and evaluation of metabolism and
pharmacokinetics/pharmacodynamics are listed
but have not been well characterized in chil-
dren and young animals. Evaluation of addi-
tional functional areas that develop postnatally,
such as the immune and genitourinary systems,
has not been extensively explored. Biomarkers
for these areas are needed, and data should be
evaluated for concordance between humans
and laboratory animals. Surrogate markers in
laboratory animals might include, for example,
pinnae detachment and eye opening. However,
the relevance of surrogate markers is question-
able and therefore should not necessarily be
included in a battery of tests for developmental
landmarks. For example, other than as a gen-
eral indication that development in the animal
is proceeding at a normal pace, the clinical sig-
niﬁcance of eye opening is nil. Furthermore,
although the ability to taste and smell can be
measured in humans and laboratory animals,
its relevance to hazard identification is
unknown.
A work group (Adams et al. 2000)
speciﬁcally charged with addressing questions
relevant to risk estimation in developmental
neurotoxicology found that, within the con-
text of methods used in regulatory testing bat-
teries, extrapolation appears stronger with
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Table 1. End point (humans and laboratory animals).
Laboratory
End point Humans animals
Survival √√
Growth and development
Body weight √√
Skeletal development  √√
(height/crown-rump)
Pinnae detachment √
Tooth eruption √√
Eye opening √
Sensory development
Hearing (auditory startle) √√
Sight √
Taste (taste aversion)
Touch (tactile startle) √
Smell (odor threshold) √√
Neuromuscular reﬂexes
Grip strength √√
Muscle coordination √√
Gait/movement √√
Activity
Spontaneous activity  √√
(hypo- and hyperactivity)
Reactivity √√
Sexual maturation
Vaginal opening √
Testes descent √√
Preputial separation √
Seconday sex characteristics √
Hormone levels √√
Learning and memory
Intelligence tests/various  √
cognitive batteries
Mazes √√
Avoidance behavior √
Operant behavior √√
Language skills √
Social behavior √√
Metabolic capability √√
Pharmacokinetics/ √√
pharmacodynamicsregard to effects on sensory and motor
functioning than for cognitive or social func-
tioning. To improve detection of learning and
memory deficits, they suggested that the
integrity of learning mechanisms should be
further challenged through task complexity.
Additionally, the workshop suggested the use
of more contemporary and sensitive methods
for evaluating behavior. These include adding
prepulse inhibition to the startle paradigm,
improving water maze learning tasks by
adding reversal learning, and examining mor-
phological and functional effects in young as
well as in aged animals.
Methods for Assessing
Potential Hazards to Children
Animal studies. Current animal toxicity
assessments include prenatal developmental
toxicity studies, fertility and reproduction
studies, developmental neurotoxicity studies,
and/or perinatal and postnatal studies.
Tables 2 and 3 are meant to summarize the
overall designs of these protocols; for detailed
descriptions the reader is referred to the origi-
nal guidelines [U.S. EPA 1991, 1996, 1998;
U.S. FDA (U.S. Food and Drug Admin-
istration) 1994]. Additionally, several reviews
discuss and compare the U.S. EPA, U.S.
FDA, and the Organisation for Economic
and Co-operation and Development guide-
lines (Collins et al. 1998; Kimmel and Makris
2001).
Generally, these protocols include
extended periods of dosing to simulate long-
term human exposure and development peri-
ods. For example, dosing extends the entire
period of gestation (implantation to term) in
the prenatal developmental study; in the
developmental neurotoxicity study, dosing
usually begins at implantation and continues
throughout prenatal development until
midway through or to completion of the
preweaning period to cover major periods of
nervous system development.
During the past four decades, considerable
effort has been expended and much experience
has been gained in the area of prenatal devel-
opmental toxicology. As a result, scientific
protocols to assess the potential for prenatal
developmental toxicity have been designed
and refined. These protocols have served us
well in identifying potential hazards to devel-
oping embryos/fetuses. The rationale for these
protocols was based (at least in part) on the
strong morphological (and presumed physio-
logical) similarity of mammalian offspring
across species, especially at the most suscepti-
ble early stages of development, when compar-
ative developmental stages are most similar.
This period encompasses differentiation and
organogenesis. As development proceeds, and
especially as it is manifested during the later
stages of prenatal development, differences
between species with regard to tissue
organization and phenotype appear, and
concordance of developmental schedules
dissipates.
Typically, assessment of postnatal toxicity
has relied on the multigenerational test, which
treats the mother 10 weeks prior to mating
through lactation and the pups themselves after
weaning to sexual maturity. The test measures
the effect of treatment on the pups’ survival,
growth and maturation, and reproductive abil-
ity. Occasionally, behavioral testing is also per-
formed on the offspring, but functional deﬁcits
(e.g., endocrine, immune, cardiovascular,
renal, hepatic) are generally not assessed in the
multigenerational test. Importantly, however,
multigenerational tests are conducted on rela-
tively few environmental chemicals and are not
routinely conducted in the course of nonclini-
cal safety testing of drug products. For phar-
maceuticals the multigeneration study has been
replaced by shorter-term studies designed to
evaluate specific developmental stages and
reproductive processes. For later-stage develop-
mental evaluations of pharmaceuticals, dams
are treated from gestation day 6 through post-
natal day (PND) 21 (the International
Conference on Harmonisation prenatal and
postnatal development paradigm), resulting in
indirect exposure to the offspring. Therefore,
gaps exist in the developmental intervals
assessed and functional areas evaluated in
conventional repeat-dose postnatal tests.
One design ﬂaw regarding exposure to the
offspring is apparent with the multigenera-
tional test and the prenatal and postnatal test
and limits their use in determining the poten-
tial postnatal toxicity of a compound. Pups
are assumed to be exposed to the compound
through the mother’s milk until weaning.
However, exposure to the compound during
the lactational period usually is not veriﬁed or
measured in these studies. As a result, expo-
sure to the offspring is uncertain and not
quantiﬁed. The compound could be excreted
or sequestered by the mother, such that the
offspring are not exposed to the extent
assumed; alternatively, the compound could
be hyperexcreted in the milk, such that the
offspring receive a much higher dose than
expected.
Another weakness associated with the
multigenerational and the prenatal and post-
natal testing paradigms is that differences
between the metabolic capacity of adults ver-
sus offspring and differences among species in
terms of organ system development are often
not well characterized (and frequently are
completely unknown). Neither of these fac-
tors should be overlooked, and as discussed
below, both should play an important role in
the choice of an appropriate animal model for
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Table 2. U.S. EPA testing guidelines.
Prenatal  Reproduction and fertility  Developmental 
development study effects (two-generation) neurotoxicity study
Dosing period GDs 6–20 (rat) P: 10 weeks prior to mating  GD 6–PND 10
GDs 6–29 (rabbit) through weaning
F: weaning through mating, 
pregnancy and lactation
Number of animals 20 pregnant females 20 pregnant females 20 litters
Typical end points  Maternal toxicity Estrous cyclicity  Offspring growth and
evaluated Number of implantations  Semen quality  viablity
and corpora lutea Mating indices Offspring toxicity
Embryo/fetal mortality Fertility indices Developmental landmarks
Fetal weight and sex Parturition  Motor activity
Fetal morphology (external,  Offspring growth and viability Auditory startle habitation
visceral, skeletal)  Reproductive landmark  Learning and memory
development (vaginal opening  Neuropathology including
and preputial separation) morphometric analysis
Reproductive organ weights 
and histopathology
Abbreviations: F, ﬁlial; GD, gestational day; P, parental.
Table 3. U.S. FDA testing guidelines.
Fertility and early Pre- and postnatal development, 
embryonic development including maternal function Embryo–fetal development
Dosing period 2 weeks (females) and  GD 6–PND 20 GDs 6–17 (rat)
4 weeks (males) prior  GDs 7–19 (rabbit)
to mating through GD 6
Typical end points  Maternal toxicity Growth and viability Maternal toxicity
evaluated Mating indices Maturation and fertility  Number of implantations 
Fertility indices indices and corpora lutea
Number of implantations  Sensory functions and reﬂexes Embryo–fetal mortality
and corpora lutea Behavior (motor activity; Fetal weight and sex
Embryo mortality learning and memory) Fetal morphology (external, 
visceral, skeletal)postnatal toxicity testing. Furthermore,
understanding the developmental differences
in organ systems across species is critical to
study design. If exposure does not occur at
the right time (i.e., during critical periods for
exposure), then potential adverse outcomes
will be missed. Additionally, if the evaluation
of the developmental milestone/process does
not occur at the right time (i.e., during the
critical periods of expression/assessment),
then again potential adverse outcomes will
be missed.
Attributes of a successful animal model. It
is difficult, if not impossible, to make an
a priori selection of an animal model for
large-scale/routine postnatal toxicity testing.
Rather, one must determine the best animal
model for each chemical entity/class. No one
model will be appropriate for all chemicals
and testing needs.
A successful (i.e., predictive) animal
model must possess four important attributes.
First, the model must be relevant; that is, it
must accurately relate to the effects associated
with chemical exposure in humans. As a pre-
requisite, it is necessary to evaluate the correct
end points (i.e., those associated with chemi-
cal exposure). Second, the model must be
sensitive; that is, it should give clear-cut
results and clearly show a dose-responsive
relationship. Third, the model must produce
reproducible (and thereby confirmable)
results so that it can be used in multiple stud-
ies conducted by different investigators in var-
ious locations. Fourth, the model must be
practical; this means it should be relatively
inexpensive and not overly work intensive.
The above attributes are required of any
successful animal model. When one is study-
ing the effect of a compound in laboratory
animals with the goal of predicting effects in
children, however, an additional condition
must be met: The target organ of the animal
model must be in the same developmental
stage as that of the humans of concern. To
meet this requirement, one must know the
developmental stage of children being
exposed, their metabolic capabilities, which
organ systems are possible targets of the study
compound, and the developmental schedules
of those organ systems in humans and in
potential test species. Armed with such infor-
mation, a researcher can choose an animal
model most appropriate for the case at hand.
One of the difficulties in choosing a
successful animal model is the compressed
developmental schedule that occurs in ani-
mals, primarily rodents. For example, regional
development of the brain proceeds in days in
rodents but in weeks to months in humans.
However, the sequence of events is compara-
ble among species (Rice and Barone 2000).
Another example is related to the reproduc-
tive system. The interval between birth and
the initiation of gametogenesis differs
between rodents (only a few days in absolute
terms) and humans (years). This short inter-
val in rodents limits interpretation of studies
on chemicals thought to bioaccumulate in
children and makes it difﬁcult to use rodents
to address questions of aggregate or intermit-
tent exposures during childhood in humans.
The appropriateness of other animal models
(rabbits and primates) should then be
explored for such studies.
Another important consideration is that
some developmental events occur postnatally
in rodents but occur prenatally in humans;
therefore, differences in route of exposures
may occur. For example, rodents have consid-
erable postnatal development of their nervous
systems, whereas humans have more prenatal
maturation; therefore, the exposures during
the same period of maturation would be dif-
ferent (i.e., lactational transfer during the ﬁrst
postnatal week in rodents and transplacental
transfer during the third trimester in
humans).
Mechanistic data. The use of information
regarding the locus of a compound’s mecha-
nism of action (generally a receptor), coupled
with the known distribution of this target,
can provide important information in the
course of predicting the pharmacology or tox-
icology of that entity. Further, known similar-
ities or discrepancies between the test species
and humans can be used to support or refute,
respectively, the relevance of animal effects for
pediatric risk assessment.
That said, traditional developmental
milestones are considered to be the result of
highly integrated processes and do not lend
themselves to in vitro mechanistic evaluation.
As with the assessment of developmental toxi-
cology, the most expedient way to evaluate
developmental milestones may be with a stan-
dardized screen to identify effects, leaving
in vitro mechanistic evaluations in the realm
of effect characterization on a case-by-case
basis. In the future, genomics and biomarkers
may be important in the detection of early
stages of xenobiotic-induced diseases in chil-
dren. However, validation is required, and as
with in vivo screening, much work is needed
to understand relevancy and clinical
implications.
Data gaps. Data gaps pertaining to hazard
identification of children’s exposure include
the lack of understanding of the relevance of
animal models for predicting outcomes in
humans, the lack of comparative developmen-
tal profiles in animal models and humans
(i.e., are the life stages studied in animal tests
analogous to human stages of concern), and
the lack of testing protocols, both of animals
and humans, evaluating functional outcomes
at relevant life stages. These data gaps should
be investigated by appropriate scientific
experimentation. Addressing these data gaps
will reduce the range of uncertainties for
children’s risk assessment.
Despite many systems undergoing
signiﬁcant development during this time, one
period with considerable data gaps is the
peripubertal/adolescent period. For example,
although prominent remodeling and matura-
tion events occur in the brain during adoles-
cence, little investigation in either humans or
animals has occurred. Another area with lim-
ited data concerns the evaluation of func-
tional deﬁcits in relation to discrete windows
of vulnerability. Rarely have early gestational
versus late gestational versus lactational
exposures been examined.
There may be a role for scientiﬁc groups
(e.g., ILSI) as well as for governmental and
regulatory agencies (e.g., U.S. EPA, U.S.
FDA) in funding landmark assessments for
development, especially postnatal develop-
ment in which there are fewer validated assays
and end points. Alternatively, end points
selected empirically to be evaluated in animal
studies could be monitored prospectively for
clinical relevance. Finally, needed information
about a given species might be ascertained
through the use of additional concurrent con-
trol groups in postnatal testing in animals.
Summary
To conduct better risk assessments of
children’s health, we must first be able to
understand the relevance of animal models for
predicting outcomes in humans. Children are
not adults. They differ by activities and stages
of development. These differences in turn can
affect how and when exposures to chemicals
occur and the resulting responses. Historically,
evaluation of developmental toxicity has
focused on gestational exposures and morpho-
logical changes resulting from this exposure.
Current processes for evaluating growth, sur-
vival, and morphological change due to gesta-
tional exposure are adequate. However,
functional consequences of gestational expo-
sure and postnatal exposure are not as well
studied. Difﬁculties with our experience and
knowledge base for postnatal toxicity evalua-
tions include divergent differentiation of
structure, function, and physiology across
species, lack of understanding of species differ-
ences in functional ontogeny, and lack of
common end points and milestones across
species.
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